Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Aastrom Biosciences Inc.
  • Aetna, Inc.
  • Agenus Inc.
  • ArQule Inc.
  • Astex Pharmaceuticals Inc.
  • Cel-Sci Corp.
  • Curis Inc.
  • Dynavax Technologies Corp.
  • Genomic Health Inc.
  • Kenrich-Eskay Mining Corp.
  • Novavax Inc.
  • Peregrine Pharmaceuticals Inc.
  • Resverlogix Corp.
  • Spectrum Pharmaceuticals Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • Threshold Pharmaceuticals
  • Zalicus Inc.

George Zavoico

MLV & Co

Image: George Zavoico

George B. Zavoico, Ph.D., has more than seven years of experience as a life sciences analyst writing research on publicly traded equities. Prior to joining MLV & Co, he worked at Westport Capital Markets LLC and Cantor Fitzgerald in their research departments. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and molecular diagnostics companies engaged in discovering, developing and marketing drugs and value-added diagnostics for the diagnosis and treatment of cancer and cardiovascular, inflammatory/immune and central nervous system diseases and disorders. Prior to working as an analyst, Zavoico established his own consulting company, serving the biotech and pharmaceutical industries by providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. He also wrote extensively on healthcare and the biotech and pharmaceutical industries for periodicals targeting the general public and industry executives. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). He has a bachelor's degree in biology from St. Lawrence University and doctorate in physiology from the University of Virginia.



Recent Interviews

10 Biotech Stocks Poised to Run: George Zavoico (3/7/13) For the first time in ages, conditions for biotech investment are just right. The capital markets have loosened up, and institutional investors are ready to bid up share prices on stories that have both merit and looming catalysts. Sure, there's risk. . .but without it, there's no upside. In this Life Sciences Report interview, Senior Analyst and Managing Director George Zavoico of MLV & Co. identifies a group of biotech companies with market-moving events on their calendars. Sharpen your pencils: From cancer to coronary artery disease to vaccine technology, Zavoico names potential winners.

The Life Sciences Report Watchlist 2013 (1/31/13) Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months.

Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico (9/13/12) Biotech has a breeze to its back, and successful progression through the phases of drug development also help propel the industry forward. In this exclusive interview with The Life Sciences Report, George Zavoico, senior analyst and managing director with MLV & Co., describes solid milestones by which investors can tick off success in the biotech space, and suggests a number of innovative biotech companies whose success will blow profits into investors' pockets.

Recent Quotes

"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >

"The trial signals a commitment from RVX to maximize the potential clinical impact of RVX-208." (10/15/12) Resverlogix Corp. - George Zavoico, MLV & Co More >

"RVX has a product with a unique mechanism of action that makes it stand out in the cholesterol-modulating space." (9/13/12) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >

"RVX announced positive top-line results for its SUSTAIN phase 2b trial." (8/29/12) Resverlogix Corp. - George Zavoico, MLV & Co More >

"If RVX is successful in identifying several BET inhibitors, this platform could be a significant value driver." (4/25/12) Resverlogix Corp. - George Zavoico, MLV & Co More >

"We think RVX's RVX-208 has demonstrated promising results." (3/22/12) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >